No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
136 |
4. Check minimum number of eventsNone |
136 |
5. Include endpointsNone |
136 |
6. Filter based on genotype QC (FinnGen only) |
133 |
Control definitions (FinnGen only)
- Control exclude
- D3_IMMUNEMECHANISM
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Other or unspecified immunodeficiency
based on the number of shared cases.
Similar with more cases:
- Other immunodeficiencies
- Immunodeficiencies
- Certain disorders involving the immune mechanism
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 792 | 445 | 340 |
| Only index persons | 679 | 396 | 283 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 41.63 | 44.77 | 37.09 |
| Only index persons | 41.98 | 44.85 | 37.96 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 133 | 85 | 48 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | 46.42 | 47.26 | 44.93 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 136
- Matched controls
- 1360
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D84.9
ICD-10 Finland
Immunodeficiency, unspecified
+∞
125.0
100
*
D84.8
ICD-10 Finland
Other specified immunodeficiencies
+∞
46.6
42
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
20.9
43.4
36
23
J32.0
ICD-10 Finland
Chronic maxillary sinusitis
10.2
31.7
43
59
J01MA14
ATC
moxifloxacin; systemic
10.4
31.6
42
56
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
14.1
31.4
32
29
TDM10
NOMESCO Finland
Puncture of maxillary antrum
13.6
30.7
32
30
UGC12
NOMESCO Finland
Flexible bronchoscopy
13.6
29.8
31
29
J01MA12
ATC
levofloxacin; systemic
7.4
29.7
63
142
J45.1
ICD-10 Finland
Nonallergic asthma
8.7
24.3
36
54
J45.0
ICD-10 Finland
Predominantly allergic asthma
7.7
24.1
41
72
J06BA01
ATC
immunoglobulins, normal human, for extravascular adm.; systemic
+∞
23.6
22
*
DMB20
NOMESCO Finland
Functional endoscopic opening of maxillary antrum
9.8
23.1
30
38
GD1AA
NOMESCO Finland
Thorax X-ray examination
6.2
22.8
98
399
J45.9
ICD-10 Finland
Asthma, unspecified
6.0
22.6
57
147
D80.1
ICD-10 Finland
Nonfamilial hypogammaglobulinaemia
+∞
22.5
21
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
5.6
21.1
58
160
H02AB07
ATC
prednisone; oral
6.2
19.9
43
95
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
5.4
19.7
55
153
R03DC03
ATC
montelukast; oral
5.4
19.4
52
139
120
Kela drug reimbursment
Hypogammaglobulinaemia
+∞
19.2
18
*
D80.9
ICD-10 Finland
Immunodeficiency with predominantly antibody defects, unspecified
+∞
18.1
17
*
J01EE01
ATC
sulfamethoxazole and trimethoprim; systemic
8.5
17.6
25
35
GD1ED
NOMESCO Finland
Extensive high resolution CT examination of lungs
23.9
17.1
24
12
UJF30
NOMESCO Finland
Ileoscopy through colon
6.6
17.0
32
61
TPH04
NOMESCO Finland
Cathetrisation of vein
4.7
16.8
56
177
DM1AA
NOMESCO Finland
Paranasal sinuses X-ray examination without contrast
20.5
16.3
24
14
ZX120
NOMESCO Finland
Intravenous
5.9
16.3
35
76
UJF32
NOMESCO Finland
Coloscopy
4.6
16.2
56
181
Z01.8
ICD-10 Finland
Other specified special examinations
4.6
16.0
53
166
D80.3
ICD-10 Finland
Selective deficiency of immunoglobulin G [IgG] subclasses
+∞
15.9
15
*
6BA02, ,
NOMESCO Finland
179.8
15.8
16
*
J01FF01
ATC
clindamycin; systemic
4.2
15.5
66
248
UDH02
NOMESCO Finland
Rhinopharyngoscopy
6.4
15.4
29
55
R03AK07
ATC
formoterol and budesonide; inhalant
4.5
15.1
49
150
H02AB06
ATC
prednisolone; systemic
4.3
15.0
91
435
J01MA02
ATC
ciprofloxacin; systemic
4.0
14.3
72
301
Z2221
NOMESCO Finland
Medical doctor
4.0
14.2
67
267
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
6.2
14.1
27
52
XQ800
NOMESCO Finland
Prick test
5.6
13.8
30
65
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.7
13.6
29
62
C01CA24
ATC
epinephrine; parenteral
6.0
13.5
27
54
R03BB04
ATC
tiotropium bromide; inhalant
6.2
13.1
25
48
TGC00
NOMESCO Finland
Bronchial lavation
27.5
12.8
17
7
D84.18
ICD-10 Finland
Other specified defect in the complement system
+∞
12.7
12
*
R03AK06
ATC
salmeterol and fluticasone; inhalant
4.4
12.7
39
113
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.8
12.5
58
225
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
5.9
12.5
25
50
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.6
12.0
66
285
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.4
11.9
36
103
D80.8
ICD-10 Finland
Other immunodeficiencies with predominantly antibody defects
+∞
11.6
11
*
J47
ICD-10 Finland
Bronchiectasis
27.8
11.4
15
6
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
6.5
11.4
20
35
WW200
NOMESCO Finland
Immunization
12.1
11.2
20
19
H02AB04
ATC
methylprednisolone; systemic
4.3
11.2
34
97
ZXD30
NOMESCO Finland
Difficulties in perfomrming procedure
6.0
11.0
21
40
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
9.5
10.8
22
27
J01.0
ICD-10 Finland
Acute maxillary sinusitis
3.4
10.7
59
252
Z3231
NOMESCO Finland
Registered nurse
3.4
10.7
60
259
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
5.7
10.4
21
42
Z3226
NOMESCO Finland
Physiotherapist
3.6
10.3
46
171
R03AC03
ATC
terbutaline; inhalant
4.1
10.3
34
103
ZXA05
NOMESCO Finland
Left side
3.5
10.3
48
184
Z31.5
ICD-10 Finland
Genetic counselling
5.1
10.0
23
52
J45
ICD-10 Finland
Asthma
4.5
9.8
27
71
D02AE01
ATC
carbamide; topical
5.8
9.7
19
37
R03AK08
ATC
formoterol and beclometasone; inhalant
9.8
9.7
19
22
ZXE00
NOMESCO Finland
One hour or less
3.1
9.6
76
395
R03AK04
ATC
salbutamol and sodium cromoglicate; inhalant
107.2
9.5
10
*
J01FA06
ATC
roxithromycin; oral
3.0
9.4
72
367
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.4
9.3
26
69
R03AC02
ATC
salbutamol; inhalant
3.4
9.3
102
635
FM1AE
NOMESCO Finland
Standard cardiac ultrasound examination
3.7
9.2
36
122
R03BA02
ATC
budesonide; inhalant
3.4
9.1
42
158
DM1AD
NOMESCO Finland
CT of paranasal sinuses and face area
8.6
9.0
19
25
ZXD10
NOMESCO Finland
Scheduled procedure
3.0
9.0
69
349
XG410
NOMESCO Finland
Flow-volume spirometry
9.2
8.9
18
22
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
4.9
8.8
21
49
GD1AD
NOMESCO Finland
Thorax CT examination
8.8
8.7
18
23
J32.4
ICD-10 Finland
Chronic pansinusitis
21.7
8.6
12
6
R50.9
ICD-10 Finland
Fever, unspecified
3.4
8.6
37
133
ZXE20
NOMESCO Finland
More than three and less than five hours
3.6
8.5
33
111
TGD04
NOMESCO Finland
Needle biopsy of the lungs in bronchoscopy
+∞
8.4
8
*
D86.0
ICD-10 Finland
Sarcoidosis of lung
+∞
8.4
8
*
R03BA01
ATC
beclometasone; inhalant
3.7
8.4
31
101
R03BA05
ATC
fluticasone; inhalant
3.1
8.2
44
181
A07AA02
ATC
nystatin; oral
6.7
8.1
20
34
XF400
NOMESCO Finland
ECG with 12 standard connections
3.5
8.0
33
115
WX002
NOMESCO Finland
Sedation and analgesia
3.2
8.0
39
151
J01DA06
ATC
[U] cefuroxime
3.4
8.0
35
127
R4110
NOMESCO Finland
Physiotherapy
2.9
7.9
55
260
A02BC03
ATC
lansoprazole; oral
2.9
7.9
52
239
A02BC02
ATC
pantoprazole; systemic
3.1
7.9
101
657
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.9
7.7
25
74
R03DA04
ATC
theophylline; systemic, rectal
9.2
7.5
15
18
Z2446
NOMESCO Finland
Social worker
4.2
7.5
22
60
R03AC12
ATC
salmeterol; inhalant
7.3
7.4
17
26
J31.0
ICD-10 Finland
Chronic rhinitis
3.9
7.4
24
71
D84.1
ICD-10 Finland
Defects in the complement system
+∞
7.4
7
*
D84.19
ICD-10 Finland
Unspecified defect in the complement system
+∞
7.4
7
*
D86.8
ICD-10 Finland
Sarcoidosis of other and combined sites
+∞
7.4
7
*
R03BA08
ATC
ciclesonide; inhalant
3.8
7.2
24
72
R96
ICPC
Asthma
4.1
7.1
21
58
A02BA02
ATC
ranitidine; systemic
3.2
7.1
34
130
ZXA10
NOMESCO Finland
Bilateral
3.0
7.0
37
149
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.6
7.0
65
353
XG470
NOMESCO Finland
Measurement of diffusion capastity of the lungs
10.1
7.0
13
14
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
3.6
6.9
25
80
R01AD09
ATC
mometasone; nasal
2.6
6.8
81
492
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
42.2
6.8
8
*
R06AX22
ATC
ebastine; oral
3.0
6.8
36
145
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
3.7
6.8
24
75
J84.1
ICD-10 Finland
Other interstitial pulmonary diseases with fibrosis
13.2
6.7
11
9
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.7
6.6
23
71
XW000
NOMESCO Finland
Bone marrow biopsy
8.1
6.6
14
19
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.9
6.6
38
161
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
3.1
6.6
32
123
R03DC01
ATC
zafirlukast; oral
15.3
6.5
10
7
J84.8
ICD-10 Finland
Other specified interstitial pulmonary diseases
19.1
6.4
9
5
J02AC01
ATC
fluconazole; systemic
2.5
6.3
69
399
R03AL02
ATC
salbutamol and ipratropium bromide; inhalant
28.1
6.3
8
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
4.0
6.3
19
53
D83.0
ICD-10 Finland
Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function
+∞
6.3
6
*
SPD00
NOMESCO Finland
Mucosa borne complete denture
+∞
6.3
6
*
J09
ICD-10 Finland
Influenza due to identified zoonotic or pandemic influenza virus
9.3
6.2
12
14
ZXE10
NOMESCO Finland
More than one and less than three hours
2.5
6.1
61
338
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
49
9
83.94
45.20
2.9
1.3
—
—
—
0
0
32
8
51.63
27.26
4.0
1.3
509.06
816.38
u/ml
—
32
8
37
66
7.33
21.26
2.9
1.5
—
—
—
0
0
28
12
28.95
20.98
2.1
1.5
861.14
621.42
e6/l
0.80
28
12
54
146
5.48
19.99
3.2
1.7
—
—
—
0
0
45
104
5.97
19.84
2.8
1.6
—
—
—
0
0
44
104
5.78
18.85
2.4
1.5
—
—
—
0
0
28
25
13.79
16.20
5.0
2.0
—
—
—
0
0
25
46
6.43
13.64
2.4
1.5
—
—
—
0
0
31
77
4.92
12.18
7.2
7.1
1.58
1.67
mmol/l
0.05
23
61
16
7
25.65
11.88
2.4
1.4
—
—
—
0
0
87
456
3.52
11.42
4.3
2.6
76.56
77.75
nmol/l
0.16
82
405
19
17
12.78
10.95
2.0
1.2
—
—
—
0
0
76
377
3.30
10.73
6.6
3.3
—
—
—
0
0
34
104
4.03
10.13
7.0
6.6
105.62
104.21
mmol/l
1.30
34
104
76
389
3.16
9.97
6.9
3.2
30.49
31.09
u/l
0.08
76
367
40
141
3.60
9.68
4.4
2.4
20.76
22.96
%
0.42
32
122
19
24
9.01
9.23
3.4
1.5
—
—
—
0
0
19
24
9.01
9.23
3.2
1.4
—
—
—
0
0
15
12
13.87
9.11
2.9
1.7
—
—
—
0
0
15
12
13.87
9.11
2.9
1.7
—
—
—
0
0
44
172
3.30
8.99
4.6
3.2
1.25
2.72
e6/l
0.96
28
94
33
111
3.61
8.49
2.8
2.4
365.33
378.76
nmol/l
0.15
33
102
62
306
2.89
8.33
5.3
3.1
0.14
0.38
e6/l
1.16
50
229
16
18
9.91
8.31
3.2
1.7
—
—
—
0
0
16
18
9.91
8.31
3.3
1.7
—
—
—
0
0
16
20
8.91
7.85
1.6
1.3
—
—
—
0
0
13
12
11.83
7.47
3.1
1.2
—
—
—
0
0
15
20
8.28
7.12
2.5
1.4
—
—
—
0
0
83
504
2.66
7.10
16.2
7.0
1.21
1.22
mmol/l
1.32
78
438
19
49
4.34
6.98
3.3
1.2
41.63
42.00
u/l
0.02
19
41
12
11
11.82
6.95
8.9
4.5
—
—
—
0
0
42
185
2.84
6.77
4.2
3.0
1.21
0.84
e6/l
0.21
26
105
20
60
3.74
5.99
1.8
1.3
—
—
—
0
0
10
9
11.87
5.90
2.8
1.1
—
—
—
0
0
40
185
2.65
5.78
4.2
3.0
1007.87
231.69
ng/l
0.52
23
125
67
394
2.38
5.78
2.3
1.8
91.76
103.32
pmol/l
1.26
42
180
15
28
5.88
5.73
2.0
1.4
1.67
0.01
iu/ml
—
6
5
49
251
2.49
5.73
4.3
3.3
2000.58
904.99
ng/l
1.04
43
203
11
14
8.44
5.46
2.7
1.3
—
—
—
0
0
13
22
6.41
5.37
1.2
1.5
—
—
—
0
0
13
22
6.41
5.37
1.2
1.5
—
—
—
0
0
12
19
6.81
5.21
1.9
1.5
—
—
—
0
0
17
51
3.67
5.08
2.0
1.6
—
—
—
0
0
10
13
8.20
4.94
2.1
1.3
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
13
25
5.63
4.91
2.8
7.3
0.23
0.40
u/ml
—
8
16
15
35
4.68
4.80
1.4
1.9
—
—
—
0
0
13
26
5.41
4.77
1.5
1.4
—
—
—
0
0
9
11
8.66
4.64
4.3
1.5
—
—
—
0
0
10
15
7.10
4.56
2.1
1.4
—
—
—
0
0
10
16
6.65
4.38
3.4
1.3
—
—
—
0
0
8
9
9.35
4.34
2.9
4.8
27.75
25.78
umol/l
—
8
9
67
434
2.07
4.19
26.4
10.6
1.21
1.22
inr
0.03
20
131
131
1158
4.57
4.13
45.2
12.1
21.61
20.49
mg/l
0.17
114
875
9
15
6.34
3.88
4.4
1.4
—
—
—
0
0
79
556
2.00
3.80
5.1
3.5
0.00
0.00
estimate
-0.00
16
116
9
16
5.94
3.72
1.2
1.2
—
—
—
0
0
45
264
2.05
3.57
2.8
2.3
—
—
—
0
0
8
13
6.46
3.55
2.5
1.2
—
—
—
0
0
13
37
3.77
3.51
1.2
1.4
—
—
—
0
0
11
27
4.34
3.48
2.2
2.2
—
—
—
0
0
122
1031
2.78
3.45
47.0
15.0
14.90
14.55
%
0.32
122
1020
8
14
6.00
3.39
2.0
2.1
—
—
—
0
0
77
554
1.90
3.31
7.5
4.9
0.00
0.00
estimate
-0.00
13
111
9
19
4.99
3.30
1.3
1.1
—
—
—
0
0
74
531
1.86
3.16
3.5
2.6
—
—
—
0
0
105
845
2.06
3.15
5.0
3.6
—
—
—
0
0
108
879
2.11
3.13
4.7
4.1
14.61
14.68
pmol/l
0.10
103
807
6
8
7.78
3.08
3.0
1.3
—
—
—
0
0
11
31
3.77
3.07
1.5
1.9
—
—
—
0
0
77
563
1.85
3.06
5.2
3.5
0.00
0.00
estimate
-0.00
15
105
5
5
10.31
3.00
1.2
1.0
—
—
—
0
0
5
5
10.31
3.00
2.8
1.0
—
—
—
0
0
9
22
4.30
2.94
2.6
1.5
—
—
—
0
0
55
366
1.84
2.93
5.1
3.1
21.88
36.42
ng/l
0.63
38
224
10
28
3.77
2.85
2.2
1.7
—
—
—
0
0
8
19
4.40
2.72
3.9
3.2
60.75
57.05
%
—
8
19
11
35
3.33
2.71
1.5
1.3
—
—
—
0
0
6
11
5.65
2.57
3.0
1.0
—
—
—
0
0
6
11
5.65
2.57
3.0
1.0
—
—
—
0
0
131
1206
3.34
2.48
41.9
13.5
81.43
72.11
umol/l
1.37
131
1206
5
8
6.43
2.39
1.0
1.0
—
—
—
0
0
11
40
2.90
2.33
12.9
8.6
1.09
1.24
%
0.40
11
40
11
40
2.90
2.33
13.6
8.5
0.65
0.70
%
0.15
11
40
18
90
2.15
2.12
8.3
3.5
—
—
—
0
0
5
10
5.14
2.09
2.0
1.2
—
—
—
0
0
118
1041
2.01
2.05
33.3
11.0
84.58
86.89
ml/min/173m2
0.44
103
827
10
39
2.69
1.99
1.2
1.2
—
—
—
0
0
8
28
2.97
1.89
1.0
1.1
—
—
—
0
0
6
17
3.64
1.86
1.3
1.1
—
—
—
0
0
40
274
1.65
1.81
1.9
1.7
—
—
—
0
0
5
13
3.95
1.73
1.4
1.2
—
—
—
0
0
10
40
2.62
1.70
3.6
5.3
1.21
1.38
%
—
10
40
11
50
2.31
1.62
1.8
1.7
230.83
281.10
miu/ml
—
6
29
7
27
2.68
1.53
1.1
1.2
—
1.43
—
0
14
5
120
0.39
1.46
13.6
5.8
—
—
—
0
0
56
434
1.49
1.45
5.8
3.5
—
—
—
0
0
39
283
1.53
1.36
5.5
3.8
63.69
10.86
mg/mmol
1.18
28
177
9
44
2.12
1.29
7.7
2.2
—
—
—
0
0
111
1004
1.57
1.23
6.4
5.2
38.44
38.75
mmol/mol
0.13
104
945
5
19
2.69
1.22
1.0
1.1
—
0.83
—
0
9
8
40
2.06
1.14
1.3
1.1
—
—
—
0
0
8
41
2.01
1.11
1.3
1.1
—
—
—
0
0
114
1045
1.56
1.10
5.8
4.8
1.98
1.89
mu/l
0.33
108
965
17
106
1.69
1.09
2.1
2.0
—
—
—
0
0
8
42
1.96
0.90
7.1
5.6
45.46
46.18
%
—
8
42
8
42
1.96
0.90
6.4
3.7
11.13
3391.78
u/ml
—
8
37
12
75
1.66
0.78
11.0
9.1
25.63
24.97
mmol/l
0.35
12
75
5
27
1.88
0.69
2.0
1.9
—
—
—
0
0
27
212
1.34
0.62
1.5
1.3
24.10
29.87
iu/ml
0.19
11
69
12
81
1.53
0.59
1.4
1.2
—
—
—
0
0
13
90
1.49
0.58
4.8
3.0
54.57
68.50
ml/min/173m2
—
7
42
6
37
1.65
0.56
5.0
1.8
—
—
—
0
0
6
38
1.61
0.55
6.0
1.9
—
—
—
0
0
112
1062
1.31
0.53
5.2
4.1
5.65
5.79
mmol/l
0.71
106
986
105
1104
0.79
0.50
4.7
4.1
1.42
1.49
mmol/l
0.77
96
1029
36
306
1.24
0.46
1.4
1.3
1.42
0.81
u/ml
0.30
13
88
12
86
1.43
0.46
2.1
1.8
—
—
—
0
0
26
213
1.27
0.45
1.7
1.3
1.11
7.80
u/ml
—
10
84
0
17
0.00
0.41
0.0
1.0
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
10
73
1.40
0.35
1.2
1.0
—
—
—
0
0
28
241
1.20
0.32
1.6
1.4
—
—
—
0
0
6
81
0.73
0.25
1.7
1.5
—
—
—
0
0
5
41
1.23
0.22
2.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
5
70
0.70
0.17
2.8
2.4
18.68
5.43
ug/l
—
5
61
109
1110
0.91
0.12
4.6
4.2
4.63
4.70
mmol/l
0.27
102
1045
17
187
0.90
0.11
3.5
4.0
23.10
21.70
%
—
7
86
104
1059
0.92
0.10
4.2
3.7
1.49
1.23
mmol/l
2.19
92
978
16
176
0.90
0.10
2.2
2.3
—
—
—
0
0
5
45
1.12
0.10
1.6
1.9
—
—
—
0
0
11
124
0.88
0.09
1.7
1.6
—
—
—
0
0
111
1121
0.95
0.04
5.1
4.6
2.73
2.80
mmol/l
0.33
99
1048
29
299
0.96
0.02
7.3
3.6
0.00
0.00
estimate
-0.00
14
107
16
156
1.03
0.00
1.9
2.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.8
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
18.00
—
0
5
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
13.43
—
0
7
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.9
—
—
—
0
0
5
53
0.94
-0.00
1.4
1.5
—
—
—
0
0
5
58
0.86
-0.00
2.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.4
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint D3_IMMUDEFNAS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_IMMUDEFNAS | 3.678 [2.42, 5.58] | < 0.001 |
| Birth year | 0.989 [0.98, 1.0] | 0.021 |
During the follow-up period (1.1.1998 — 31.12.2019), 88 out of 387 females with D3_IMMUDEFNAS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_IMMUDEFNAS | 2.774 [1.85, 4.16] | < 0.001 |
| Birth year | 0.986 [0.97, 1.0] | 0.025 |
During the follow-up period (1.1.1998 — 31.12.2019), 69 out of 289 males with D3_IMMUDEFNAS died.
Mortality risk
Mortality risk for people of age
years, who have D3_IMMUDEFNAS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.294% | 0.457% |
| 5 | 1.697% | 3.098% |
| 10 | 4.35% | 8.007% |
| 15 | 8.053% | 14.237% |
| 20 | 14.103% | 23.103% |
Relationships between endpoints
↥Index endpoint: D3_IMMUDEFNAS – Other or unspecified immunodeficiency
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data